<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098462</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000401501</org_study_id>
    <secondary_id>UCLA-0407057-01</secondary_id>
    <secondary_id>ZENECA-IRUSIRES0281</secondary_id>
    <nct_id>NCT00098462</nct_id>
  </id_info>
  <brief_title>Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Trial of ZD1839 (Iressa®) and Rapamycin (Rapamune) in Patients With Advanced Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Sometimes when chemotherapy is given, it does not stop the growth of tumor cells.&#xD;
      The tumor is said to be resistant to chemotherapy. Giving gefitinib together with sirolimus&#xD;
      may reduce drug resistance and allow the tumor cells to be killed.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of sirolimus when&#xD;
      given with gefitinib and to see how well they work in treating patients with recurrent or&#xD;
      refractory stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of sirolimus when combined with gefitinib in&#xD;
           patients with recurrent or refractory stage IIIB or IV non-small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall response rate (complete response [CR] and partial response [PR])&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the disease control rate (CR, PR, and stable disease) in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the time to progression and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, phase I, dose-escalation study of sirolimus followed by a&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive oral gefitinib once daily and oral sirolimus once daily on&#xD;
           days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or&#xD;
           disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of sirolimus until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive gefitinib and sirolimus as in phase I at the MTD. Quality of&#xD;
           life is assessed at baseline, day 1 of each course, and then at 1 month&#xD;
           post-progression.&#xD;
&#xD;
      Patients are followed every 9 weeks. Patients withdrawn from study treatment without evidence&#xD;
      of disease progression are followed every 6 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients (11 for phase I and 14 for phase II) will be&#xD;
      accrued for this study within 8.3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn as study never opened&#xD;
  </why_stopped>
  <start_date>October 2004</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (Phase I)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response (complete response [CR] and partial response [PR]) as measured by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR, PR, and stable disease) correlated with smoking history</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung cancer subscale from FACT-L</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIB or IV disease&#xD;
&#xD;
          -  Recurrent or refractory disease&#xD;
&#xD;
               -  Received ≥ 1 prior platinum-containing chemotherapy regimen&#xD;
&#xD;
          -  Unidimensionally measurable disease that has not been irradiated&#xD;
&#xD;
          -  No newly diagnosed untreated brain metastases or spinal cord compression&#xD;
&#xD;
          -  Paraffin-embedded tumor tissue or slides available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  No severe or uncontrolled hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Creatinine ≤ 3.0 times upper limit of normal&#xD;
&#xD;
          -  No severe or uncontrolled renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Adequate cardiac function&#xD;
&#xD;
          -  No severe or uncontrolled cardiac disease&#xD;
&#xD;
          -  No uncontrolled hyperlipidemia&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No unstable or uncompensated respiratory disease&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
               -  Patients with chronic stable radiographic changes who are asymptomatic are&#xD;
                  eligible&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  No gastrointestinal condition (e.g., peptic ulcer disease) that would affect&#xD;
             absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No known severe hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No other malignancy within the past 5 years except treated basal cell or squamous cell&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other severe or uncontrolled systemic disease&#xD;
&#xD;
          -  No significant clinical disorder or laboratory finding that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 14 days since prior biologic therapy&#xD;
&#xD;
          -  No prior cetuximab, panitumumab, or bevacizumab&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior oncologic or other major surgery&#xD;
&#xD;
          -  No prior gastrointestinal surgery affecting absorption&#xD;
&#xD;
          -  No concurrent surgery, including ophthalmic surgery, during and for 1 week after study&#xD;
             treatment&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No other prior HER1/epidermal growth factor receptor axis agents, including the&#xD;
             following:&#xD;
&#xD;
               -  Gefitinib&#xD;
&#xD;
               -  Erlotinib&#xD;
&#xD;
               -  CI-1033&#xD;
&#xD;
               -  Lapatinib&#xD;
&#xD;
          -  No other prior vascular endothelial growth factor axis agents, including the&#xD;
             following:&#xD;
&#xD;
               -  ZD6474&#xD;
&#xD;
               -  Vatalanib&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers, including the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No other concurrent systemic treatment for the malignancy&#xD;
&#xD;
          -  No concurrent bisphosphonates for symptomatic bone metastases&#xD;
&#xD;
          -  No concurrent systemic retinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fairooz F. Kabbinavar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

